Dmytro Kharkov

Eli Lilly up 4.14% as shares challenge clustered resistance, supported by robust drug sales – weekly review

Eli Lilly up 4.14% as shares challenge clustered resistance, supported by robust drug sales – weekly review
Eli Lilly rises 4.14% this week

Eli Lilly and Company (LLY) is trading at $1,051.29 this week, reflecting an increase of $29.27, or 2.86%. The stock remains above both its MA-20 ($1,036.33) and MA-200 ($874.42), but sits just below the MA-50 ($1,053.10), signaling strong short- and long-term bullish momentum, with slight resistance at the medium-term average.

LLY price prediction
24H -0.34%
$1,427.44
48H -0.58%
$1,424.09
7D -1.23%
$1,414.72
1M 11.08%
$1,591.09
3M 33.84%
$1,917.01
6M 18.31%
$1,694.64
12M 42.73%
$2,044.39
Current price: $1,432.36 -12.4400 0.86%
Closed 11/16
Daily range 1428.22 Arrow from to Icon 1469.75
Weekly range 1409.03 Arrow from to Icon 1469.75
Loading...

Highlights

  • Eli Lilly shares closed at $1,051.29, maintaining a strong bullish momentum above the MA-20 ($1,036.33) and MA-200 ($874.42), with minor resistance just below the MA-50 ($1,053.10).
  • Oscillators such as Stochastic RSI, Bull/Bear Power, and others show overbought conditions, signaling stretched near-term levels despite buyers dominating intraday flow and a 2.86% gain.
  • Key resistance sits at $1,053.79 (Ichimoku Kijun/MA-50), with a weekly range of $1,040–$1,095 and >80% probability of further upside in the coming week.

Growth in GLP-1 drug sales sustains optimism amid elevated valuations

Eli Lilly's rapid growth continues as its GLP-1 drugs, particularly Mounjaro and Zepbound, drive strong business performance, with Zepbound recently approved for weight loss. The company is operating with a high price-to-earnings ratio of about 45 and has reaffirmed its commitment to maintaining its current dividend level of roughly 0.6%. Ongoing business challenges are being managed alongside high market expectations for its leadership in the GLP-1 segment.

Overbought weekly signals as price nears clustered resistance zone

On the weekly (W1) chart, LLY holds above the MA-20 and MA-200, indicating a clear bullish trend, while the MA-50 at $1,053.10 and the Ichimoku Kijun near $1,053.79 form a tightly clustered resistance area just above current prices. Weekly support is seen at $1,040, and resistance stands near $1,055 and extends up towards $1,095. Oscillators such as the weekly RSI are in overbought territory, and despite persistent buying pressure, mixed momentum signals from indicators like the MACD and ADX suggest the trend’s strength could be moderating near these levels.

Consolidation likely in the coming week as overbought risks mount

For the next 5–7 trading days, LLY is expected to consolidate within a weekly range of $1,040 to $1,095, reflecting typical volatility for a large-cap stock after a strong run. A breakout above $1,055 would likely target new highs, with the upper boundary near $1,095, while a move below $1,040 could trigger a pullback towards dynamic support areas. The probability of a continued advance remains high, but overbought conditions and resistance near current levels warrant caution for aggressive new entries.
Viktoras Karapetjanc, analyst at Traders Union, sees Eli Lilly maintaining a robust bullish structure for the week. The stock remains in a clear uptrend above its MA-20 and MA-200, with strong business momentum supported by the success of its GLP-1 portfolio. Macro sentiment remains positive as high market expectations and steady dividend policies reinforce institutional demand. While resistance around $1,055 and overbought weekly signals suggest some consolidation, the overall setup favors further growth within the $1,040 to $1,095 band. "In my view, bullish momentum is intact, and I expect Eli Lilly to offer solid opportunity for upside continuation in the coming week."
Previously it was reported that Eli Lilly is trading just above its short-term moving average but remains below medium-term resistance, with long-term technical support firmly intact. Momentum indicators show mixed signals—MACD highlights recent selling pressure while RSI, Stochastic RSI, and CCI hover near neutral to slightly oversold—and resistance near $1,053 remains significant, suggesting near-term upside is limited without stronger confirmation from trend indicators.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.